Extensive evidence from three decades of research has established that diminished cerebral glucose metabolism (DCGM, also known as glucose hypometabolism) is a key underlying pathology in the Alzheimer’s brain.1 This leaves neurons less able to utilize glucose for fuel, leading to an energy shortage in the brain.1 DCGM occurs early in the disease and correlates with symptoms and disease progression.5-9
Axona is the only available prescription medical food that addresses DCGM.2,4 Unlike the FDA-approved drug classes called acetylcholinesterase inhibitors (AChEIs) and N-methyl-D-aspartic acid (NMDA) receptor antagonists, Axona provides medium-chain triglycerides to the body that can be metabolized into ketone bodies as an alternative fuel source for the brain.3,4
Add Axona. Add what's been missing from Alzheimer's therapy.
Axona is a prescription medical food intended for the clinical dietary management of the metabolic processes associated with mild to moderate Alzheimer’s disease.
Read Accera's response to the recent FDA warning letter.